|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Betaxolol#Use in Specific Populations]] |
| {{Betaxolol}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Use In Specific Populations==
| |
| | |
| ===Pregnancy===
| |
| | |
| '''Pregnancy Category C'''. Reproduction, teratology, and peri- and postnatal studies have been conducted with orally administered betaxolol HCl in rats and rabbits. There was evidence of drug related postimplantation loss in rabbits and rats at dose levels above 12 mg/kg and 128 mg/kg, respectively. Betaxolol HCl was not shown to be teratogenic, however, and there were no other adverse effects on reproduction at subtoxic dose levels. There are no adequate and well-controlled studies in pregnant women. BETOPTIC Ophthalmic Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
| |
| | |
| ===Nursing Mothers===
| |
| | |
| It is not known whether betaxolol HCl is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when BEOPTIC Ophthalmic Solution is administered to nursing women.
| |
| | |
| ===Pediatric Use===
| |
| | |
| Safety and effectiveness in pediatric patients have not been established.
| |
| | |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BETOPTIC (BETAXOLOL HYDROCHLORIDE) SOLUTION/ DROPS [ALCON] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=31b9b263-11fd-4495-83dd-ababf0d70e9e | publisher = | date = | accessdate = 3 February 2014 }}</ref>
| |
| | |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
|
| |
|
| [[Category:Beta blockers]] | | [[Category:Beta blockers]] |
| [[Category:Cardiovascular Drugs]] | | [[Category:Cardiovascular Drugs]] |
| [[Category:Drugs]] | | [[Category:Drugs]] |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |